Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments

Journal of Immunological Methods

Volumn 287, Issue 1-2, 2004, Pages 147-158

  Cochran, Jennifer R ^a   Kim, Yong Sung ^a   Olsen, Mark J ^a   Bhandari, Rashna ^b,c   Wittrup, K Dane ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; Epitope mapping; hEGF; Human epidermal growth factor; mAb; Monoclonal antibody; Protein domain; Yeast display

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ARTICLE; BINDING ASSAY; CELL SURFACE; CONTROLLED STUDY; DENATURATION; EPITOPE MAPPING; FLUORESCENCE; HEAT; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN STABILITY; SACCHAROMYCES CEREVISIAE; TECHNIQUE; YEAST; YEAST SURFACE DISPLAY;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; ANTIGENS, SURFACE; BINDING, COMPETITIVE; EPITOPE MAPPING; HUMANS; IMMUNOASSAY; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SACCHAROMYCES CEREVISIAE;

SACCHAROMYCES;

EID: 1942520362     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2004.01.024     Document Type: Article

References (50)

1. Baron A.T., Huntley B.K., Lafky J.M., Reiter J.L., Liebenow J., McCormick D.J., Ziesmer S.C., Roche P.C., Maihle N.J. Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain. Hybridoma. 16:1997;259.
2. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15:1997;553.
3. Boder E.T., Wittrup K.D. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol. 328:2000;430.
4. Boder E.T., Midelfort K.S., Wittrup K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10701.
5. Carpenter G., Cohen S. Epidermal growth factor. J. Biol. Chem. 265:1990;7709.
6. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099.
7. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756.
8. Christmann A., Wentzel A., Meyer C., Meyers G., Kolmar H. Epitope mapping and affinity purification of monospecific antibodies by Escherichia coli cell surface display of gene-derived random peptide libraries. J. Immunol. Methods. 257:2001;163.
9. Cunningham B.C., Jhurani P., Ng P., Wells J.A. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science. 243:1989;1330.
10. Dean C., Modjtahedi H., Eccles S., Box G., Styles J. Immunotherapy with antibodies to the EGF receptor. Int. J. Cancer, Suppl. 8:1994;103.
11. Elleman T.C., Domagala T., McKern N.M., Nerrie M., Lonnqvist B., Adams T.E., Lewis J., Lovrecz G.O., Hoyne P.A., Richards K.M., Howlett G.J., Rothacker J., Jorissen R.N., Lou M., Garrett T.P., Burgess A.W., Nice E.C., Ward C.W. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry. 40:2001;8930.
12. Ellgaard L., Helenius A. Quality control in the endoplasmic reticulum. Nat. Rev., Mol. Cell Biol. 4:2003;181.
13. Feldhaus M.J., Siegel R.W., Opresko L.K., Coleman J.R., Feldhaus J.M., Yeung Y.A., Cochran J.R., Heinzelman P., Colby D., Swers J., Graff C., Wiley H.S., Wittrup K.D. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. 21:2003;163.
14. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11:2003;507.
15. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 110:2002;763.
16. Gill G.N., Kawamoto T., Cochet C., Le A., Sato J.D., Masui H., McLeod C., Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259:1984;7755.
17. Hong W.K., Ullrich A. The role of EGFR in solid tumors and implications for therapy. Oncol. Biother. 1:2000;1.
18. Itoh K., Inoue K., Tezuka T., Tada H., Hashimoto Y., Masuko T., Suzuki T. Molecular structural and functional characterization of tumor suppressive anti-ErbB-2 monoclonal antibody by phage display system. J. Biochem. (Tokyo). 133:2003;239.
19. Jorissen R.N., Epa V.C., Treutlein H.R., Garrett T.P., Ward C.W., Burgess A.W. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor. Protein Sci. 9:2000;310.
20. Kohda D., Odaka M., Lax I., Kawasaki H., Suzuki K., Ullrich A., Schlessinger J., Inagaki F. A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. J. Biol. Chem. 268:1993;1976.
21. Kudlow J.E., Khosravi M.J., Kobrin M.S., Mak W.W. Inability of anti-epidermal growth factor receptor monoclonal antibody to block "autocrine" growth stimulation in transforming growth factor-secreting melanoma cells. J. Biol. Chem. 259:1984;11895.
22. Lax I., Burgess W.H., Bellot F., Ullrich A., Schlessinger J., Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol. Cell Biol. 8:1988;1831.
23. Lax I., Bellot F., Honegger A.M., Schmidt A., Ullrich A., Givol D., Schlessinger J. Domain deletion in the extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression. Cell Regul. 1:1990;173.
24. Lax I., Fischer R., Ng C., Segre J., Ullrich A., Givol D., Schlessinger J. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. Cell Regul. 2:1991;337.
25. Lemmon M.A., Bu Z., Ladbury J.E., Zhou M., Pinchasi D., Lax I., Engelman D.M., Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16:1997;281.
26. Limbird L.E. Cell Surface Receptors: A Short Course on Theory and Methods. 1996;Kluwer Academic Publishing, Boston, MA.
27. Masui H., Kawamoto T., Sato J.D., Wolf B., Sato G., Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44:1984;1002.
28. Meilhoc E., Masson J.M., Teissie J. High efficiency transformation of intact yeast cells by electric field pulses. Biotechnology (N.Y.). 8:1990;223.
29. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550.
30. Mischo A., Wadle A., Watzig K., Jager D., Stockert E., Santiago D., Ritter G., Regitz E., Jager E., Knuth A., Old L., Pfreundschuh M., Renner C. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immunol. 3:2003;5.
31. Modjtahedi H., Dean C. The growth-response of human tumor-cell lines expressing the EGF receptor to treatment with EGF and or mAbs that block ligand binding. Int. J. Oncol. 3:1993;237.
32. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 37(Suppl. 4):2001;S9.
33. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775.
34. Richert N.D., Willingham M.C., Pastan I. Epidermal growth factor receptor. Characterization of a monoclonal antibody specific for the receptor of A431 cells. J. Biol. Chem. 258:1983;8902.
35. Sato J.D., Kawamoto T., Le A.D., Mendelsohn J., Polikoff J., Sato G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1:1983;511.
36. Shusta E.V., Kieke M.C., Parke E., Kranz D.M., Wittrup K.D. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J. Mol. Biol. 292:1999;949.
37. Shusta E.V., Holler P.D., Kieke M.C., Kranz D.M., Wittrup K.D. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. Biotechnol. 18:2000;754.
38. Sikorski R.S., Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics. 122:1989;19.
39. Stein R.A., Wilkinson J.C., Guyer C.A., Staros J.V. An analytical approach to the measurement of equilibrium binding constants: application to EGF binding to EGF receptors in intact cells measured by flow cytometry. Biochemistry. 40:2001;6142.
40. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. U. S. A. 87:1990;8602.
41. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203.
42. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J.et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418.
43. van Zonneveld A.J., van den Berg B.M., van Meijer M., Pannekoek H. Identification of functional interaction sites on proteins using bacteriophage-displayed random epitope libraries. Gene. 167:1995;49.
44. Waterfield M.D., Mayes E.L., Stroobant P., Bennet P.L., Young S., Goodfellow P.N., Banting G.S., Ozanne B. A monoclonal antibody to the human epidermal growth factor receptor. J. Cell Biochem. 20:1982;149.
45. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J., Traweek S.T., Wong A.J., Zalutsky M.R., Bigner D.D. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:1995;3140.
46. Wu D.G., Wang L.H., Sato G.H., West K.A., Harris W.R., Crabb J.W., Sato J.D. Human epidermal growth factor (EGF) receptor sequence recognized by EGF competitive monoclonal antibodies. Evidence for the localization of the EGF-binding site. J. Biol. Chem. 264:1989;17469.
47. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G., Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1999;1236.
48. Yip Y.L., Smith G., Koch J., Dubel S., Ward R.L. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol. 166:2001;5271.
49. Yip Y.L., Novotny J., Edwards M., Ward R.L. Structural analysis of the ErbB-2 receptor using monoclonal antibodies: implications for receptor signalling. Int. J. Cancer. 104:2003;303.
50. Zhan H., Liu B., Reid S.W., Aoki K.H., Li C., Syed R.S., Karkaria C., Koe G., Sitney K., Hayenga K., Mistry F., Savel L., Dreyer M., Katz B.A., Schreurs J., Matthews D.J., Cheetham J.C., Egrie J., Giebel L.B., Stroud R.M. Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin. Protein Eng. 12:1999;505.